Is Clover Health Investments, Corp. (NASDAQ:CLOV) a buy in 2026?
Yes, on balance. The Compass leans toward accumulating Clover Health Investments, Corp. at current levels.
Clover's software-first Medicare Advantage model is finally producing cash, and the Street still treats it like a 2021 SPAC zombie.
Where CLOV is headed
Clover Health (NASDAQ:CLOV) in mid-2027 looks almost nothing like the meme-stock punchline it was four years ago. Revenue is running at a roughly $3 billion pace, free cash flow has crossed $150 million on a 5% margin, and the Clover Assistant software is doing the unglamorous work it was always meant to do: catching chronic conditions early in a Medicare Advantage population where every avoided ER visit drops straight to the bottom line. The MA industry around them is a wreck. UnitedHealth is bleeding from V28 risk adjustment changes, Humana is restructuring, Centene is firefighting. Clover, paradoxically, benefits from being small, late to the party, and built around a software layer rather than acquired physician groups.
Read the full Compass Direction on CLOV
The complete destination call, the overlooked angle, milestones, and bull, base, and bear price scenarios (around $4.29).
See the full CLOV analysisGet calls like this, free
Join the Alexandria e-letter for forward-looking verdicts, earnings intelligence, and the contrarian reads the crowd misses. Twice a week, no noise.
Free forever. Unsubscribe anytime. We never share your email.
Frequently asked questions
Is Clover Health Investments, Corp. (NASDAQ:CLOV) a buy in 2026?
Yes, on balance. The Compass leans toward accumulating Clover Health Investments, Corp. at current levels. Clover's software-first Medicare Advantage model is finally producing cash, and the Street still treats it like a 2021 SPAC zombie.
What is CLOV's Compass Score?
Clover Health Investments, Corp. scores 89/100 on Alexandria's Compass, placing it in the "True North" tier. Scores blend eight factors and update weekly.
What is the price target for CLOV?
Alexandria's full Compass Direction includes bull, base, and bear price scenarios with the valuation math behind each. Read the full breakdown on the CLOV page.
Compass verdicts are AI-generated, forward-looking editorial research from publicly available data, not investment advice or a recommendation regarding any security. Scores and verdicts update as the data changes.